Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H18O3 |
Molecular Weight | 282.3337 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CCC[C@@]1([H])C3=CC(O)=CC=C3O[C@H]2C4=CC=C(O)C=C4
InChI
InChIKey=XIESSJVMWNJCGZ-VKJFTORMSA-N
InChI=1S/C18H18O3/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(20)8-9-17(16)21-18/h4-10,14-15,18-20H,1-3H2/t14-,15+,18+/m1/s1
Molecular Formula | C18H18O3 |
Molecular Weight | 282.3337 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17034120Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800031986 | https://www.ncbi.nlm.nih.gov/pubmed/27126081
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17034120
Curator's Comment: description was created based on several sources, including:
http://adisinsight.springer.com/drugs/800031986 | https://www.ncbi.nlm.nih.gov/pubmed/27126081
Synthetic compound Erteberel (LY500307) is a highly potent and selective ERβ agonist; it has a 12-fold higher affinity for ERβ than ERα and exhibits 32-fold more functional potency. LY500307 was well tolerated in benign prostatic hypertrophy (BPH) patients with no side effects and it is currently being tested in phase 2 clinical trials for improving negative symptoms and cognitive impairment associated with Schizophrenia. In BPH clinical trial incidence of adverse events was comparable between treatment groups, and no clinically meaningful changes in laboratory tests were observed.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800031986
Curator's Comment: https://www.giiresearch.com/report/labd240920-eli-lilly-company-product-pipeline-review.html # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17034120 |
0.19 nM [Ki] | ||
Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17034120 |
2.68 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25348255
1, 3, 10 and 25 mg once daily for 24 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27126081
LY500307 (5 uM during 24 h) treatment significantly increased the percentage of cells in G2/M phase in U87, U251, LN229 and GBM10 cells when compared to vehicle.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:45:59 GMT 2023
by
admin
on
Fri Dec 15 18:45:59 GMT 2023
|
Record UNII |
2ZUL6758TZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70201547
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
Erteberel
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
XX-46
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
C166610
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
300000034215
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
DB07933
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
2ZUL6758TZ
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
9363
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
533884-09-2
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
10286159
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL278703
Created by
admin on Fri Dec 15 18:45:59 GMT 2023 , Edited by admin on Fri Dec 15 18:45:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|